Phase 1/2CompletedAge-related condition
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis
- Sponsor
- Prothena Biosciences Ltd. (Industry)
- Enrolment
- 69 enrolled
- Conditions
- Primary Amyloidosis
- Interventions
- NEOD001
- Ages
- adults, older adults
- Registry
- NCT01707264
Full record on ClinicalTrials.gov
From the registry
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.
Primary outcomes
- Safety and tolerability
- Maximum tolerated dose
History
Last registry update
Primary completion
Started
Registered